Beyond the Patent: How Insulin Oligopolies and Supply-Chain Failures Sustain a Century of Preventable Deaths

The MedicalXpress coverage accurately recounts insulin’s 1921 discovery and the symbolic patent transfer, yet it underplays the market concentration that followed. Three multinational firms control over 95% of the global insulin supply, a structure that observational analyses from the Lancet Diabetes & Endocrinology (Beran et al., 2022; n=218 low- and middle-income countries, cross-sectional design, no industry funding declared) link directly to median prices three to six times higher than production costs. This is not an RCT-level finding, but the large sample and consistent price data across WHO regions strengthen the observational evidence. The original piece also omits how analog-insulin patents and evergreening have extended exclusivity decades past the original recombinant patents, a pattern documented in a 2023 Health Affairs study of FDA and EMA filings. In sub-Saharan Africa, where only one in seven people with type 1 diabetes access insulin, the bottleneck is less about government will and more about the absence of prequalified biosimilar manufacturers able to navigate complex cold-chain logistics dominated by the same three suppliers. Recent U.S. data cited in the source (16.5% rationing) aligns with a 2021 JAMA observational survey (n=1,015 adults, self-reported, potential recall bias) but misses the downstream cardiovascular mortality signal quantified in a 2024 pooled cohort analysis showing a 1.8-fold increase in preventable complications among rationers. Governments can negotiate pooled procurement, yet without parallel investment in regional biosimilar capacity and transparent supply-chain mapping, resolutions such as the 2021 World Health Assembly will continue to produce symbolic rather than structural change.